Compare Abeona Therapeutics Inc (ABEO) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $424.33M), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | EMB | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Fixed Income |
52-Week High | $7.45 | $97.74 |
52-Week Low | $4.17 | $92.95 |
Enterprise Value | $279.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.
Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
